Skip to main content
Top
Published in: Inflammation 1/2014

01-02-2014

Serum Analysis of Coagulation Factors in IPF and NSIP

Authors: E. Bargagli, C. Madioni, N. Bianchi, R. M. Refini, R. Cappelli, P. Rottoli

Published in: Inflammation | Issue 1/2014

Login to get access

Abstract

Recent literature and our previous proteomic findings prompted us to study the coagulation system in idiopathic pulmonary fibrosis (IPF), the pathogenesis of which remains unclear. The aim of this study was to compare coagulation factors in idiopathic pulmonary fibrosis and idiopathic nonspecific interstitial pneumonia (NSIP) patients and healthy controls. Thirty-three IPF patients (23 acute exacerbation and 10 stable IPF patients), 7 NSIP patients, and 44 controls were enrolled. Concentrations of D-dimer, homocysteine, functional protein C, protein C antigen, free and total protein S antigen and activity, fibrinogen and factor VIIIc were analyzed in serum of patients and controls. The lupus anticoagulant (LAC) test was also performed. Factor VIIIc levels were significantly higher in acute exacerbation IPF patients than controls (p = 0.0001) and in stable IPF patients than controls (p = 0.002). Factor VIIIc levels were higher and PT levels were lower in acute exacerbation IPF patients who died after exacerbation than in patients who survived (p = 0.04 and p = 0.003, respectively). D-dimer, fibrinogen, and homocysteine levels were also significantly higher in IPF patients than controls (p < 0.01). Protein C activity was increased in acute exacerbation IPF patients than controls (p = 0.005). The LAC test was positive in seven IPF patients and negative in controls. Procoagulant status was demonstrated in IPF patients (mainly in acute exacerbation/IPF) than controls and NSIP patients, probably due to endothelial activation and microvascular injury. These preliminary results are of interest because of their potential implications in the pathogenesis and treatment of this disease.
Literature
1.
go back to reference Raghu, G., H.R. Collard, J.J. Egan, et al. 2011. AN official ATS/ERS/JRS/ALAT statement: IPF evidence-based guidelines for diagnosis and treatment. American Journal of Respiratory and Critical Care Medicine 183: 788–824.CrossRef Raghu, G., H.R. Collard, J.J. Egan, et al. 2011. AN official ATS/ERS/JRS/ALAT statement: IPF evidence-based guidelines for diagnosis and treatment. American Journal of Respiratory and Critical Care Medicine 183: 788–824.CrossRef
2.
go back to reference Chambers, R.C. 2008. Abnormal wound healing responses in pulmonary fibrosis: focus on coagulation signalling. European Respiratory Review 17(109): 130–137.CrossRef Chambers, R.C. 2008. Abnormal wound healing responses in pulmonary fibrosis: focus on coagulation signalling. European Respiratory Review 17(109): 130–137.CrossRef
3.
go back to reference Wygrecka, M., P. Markart, C. Ruppert, et al. 2007. Cellular origin of pro-coagulant and antifibrinolytic factors in bleomycin-injured lungs. European Respiratory Journal 29: 1105–1114.CrossRef Wygrecka, M., P. Markart, C. Ruppert, et al. 2007. Cellular origin of pro-coagulant and antifibrinolytic factors in bleomycin-injured lungs. European Respiratory Journal 29: 1105–1114.CrossRef
4.
go back to reference Chambers, R.C. 2008. Procoagulant signalling mechanisms in lung inflammation and fibrosis: new opportunities for pharmacological intervention? British Journal of Pharmacology 153: S367–S378.CrossRef Chambers, R.C. 2008. Procoagulant signalling mechanisms in lung inflammation and fibrosis: new opportunities for pharmacological intervention? British Journal of Pharmacology 153: S367–S378.CrossRef
5.
go back to reference Wygrecka, M., E. Jablonska, A. Guenther, et al. 2008. Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases. Thrombosis and Haemostasis 99: 494–501.CrossRef Wygrecka, M., E. Jablonska, A. Guenther, et al. 2008. Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases. Thrombosis and Haemostasis 99: 494–501.CrossRef
6.
go back to reference Ma, L., and A. Dorling. 2012. The roles of thrombin and protease-activated receptors in inflammation. Seminars in Immunopathology 34: 63–72.CrossRef Ma, L., and A. Dorling. 2012. The roles of thrombin and protease-activated receptors in inflammation. Seminars in Immunopathology 34: 63–72.CrossRef
7.
go back to reference Kubo, H., K. Nakayama, M. Yanai, et al. 2005. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 128: 1475–1482.CrossRef Kubo, H., K. Nakayama, M. Yanai, et al. 2005. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 128: 1475–1482.CrossRef
8.
go back to reference Magro, C.M., W.J. Waldman, D.A. Knight, et al. 2006. Idiopathic pulmonary fibrosis related to endothelial injury and antiendothelial cell antibodies. Human Immunology 67: 284–297.CrossRef Magro, C.M., W.J. Waldman, D.A. Knight, et al. 2006. Idiopathic pulmonary fibrosis related to endothelial injury and antiendothelial cell antibodies. Human Immunology 67: 284–297.CrossRef
9.
go back to reference Scotton, C.J., M.A. Krupiczojc, M. Königshoff, et al. 2009. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. The Journal of Clinical Investigation 119: 2550–2563.PubMedPubMedCentral Scotton, C.J., M.A. Krupiczojc, M. Königshoff, et al. 2009. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. The Journal of Clinical Investigation 119: 2550–2563.PubMedPubMedCentral
10.
go back to reference Magro, C.M., J. Allen, A. Pope-Harman, et al. 2003. The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis. American Journal of Clinical Pathology 203: 556–567.CrossRef Magro, C.M., J. Allen, A. Pope-Harman, et al. 2003. The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis. American Journal of Clinical Pathology 203: 556–567.CrossRef
11.
go back to reference Magi, B., E. Bargagli, L. Bini, and P. Rottoli. 2006. Proteome analysis of bronchoalveolar lavage in lung diseases. Proteomics 6: 6354–6369.CrossRef Magi, B., E. Bargagli, L. Bini, and P. Rottoli. 2006. Proteome analysis of bronchoalveolar lavage in lung diseases. Proteomics 6: 6354–6369.CrossRef
12.
go back to reference Collard, H.R., C.S. Calfee, P.J. Wolters, et al. 2010. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. American Journal of Physiology. Lung Cellular and Molecular Physiology 299: L3–L7.CrossRef Collard, H.R., C.S. Calfee, P.J. Wolters, et al. 2010. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. American Journal of Physiology. Lung Cellular and Molecular Physiology 299: L3–L7.CrossRef
13.
go back to reference Sangle, N.A., and K.J. Smock. 2011. Antiphospholipid antibody syndrome. Archives of Pathology & Laboratory Medicine 135: 1092–1096.CrossRef Sangle, N.A., and K.J. Smock. 2011. Antiphospholipid antibody syndrome. Archives of Pathology & Laboratory Medicine 135: 1092–1096.CrossRef
14.
go back to reference Erkan, D., H. Bateman, and M.D. Lockshin. 1999. Lupus anticoagulant-hypoprothrombinemia syndrome associated with systemic lupus erythematosus: report of two cases and review of literature. Lupus 8: 560–564.CrossRef Erkan, D., H. Bateman, and M.D. Lockshin. 1999. Lupus anticoagulant-hypoprothrombinemia syndrome associated with systemic lupus erythematosus: report of two cases and review of literature. Lupus 8: 560–564.CrossRef
15.
go back to reference Visseaux, B., J. Masliah-Planchon, A.M. Fischer, et al. 2011. Antiphospholipid syndrome diagnosis: an update. Annales de Biologie Clinique (Paris) 69: 411–418.CrossRef Visseaux, B., J. Masliah-Planchon, A.M. Fischer, et al. 2011. Antiphospholipid syndrome diagnosis: an update. Annales de Biologie Clinique (Paris) 69: 411–418.CrossRef
16.
go back to reference Mehra, R., F. Xu, D.C. Babineau, et al. 2010. Sleep-disordered breathing and prothrombotic biomarkers: cross-sectional research of the Cleveland Family Study. American Journal of Respiratory and Critical Care Medicine 182: 826–833.CrossRef Mehra, R., F. Xu, D.C. Babineau, et al. 2010. Sleep-disordered breathing and prothrombotic biomarkers: cross-sectional research of the Cleveland Family Study. American Journal of Respiratory and Critical Care Medicine 182: 826–833.CrossRef
17.
go back to reference Battistelli, S., A. Vittoria, R. Cappelli, et al. 2005. Protein S in cancer patients with non metastatic solid tumors. European Journal of Surgical Oncology 31: 798–802.CrossRef Battistelli, S., A. Vittoria, R. Cappelli, et al. 2005. Protein S in cancer patients with non metastatic solid tumors. European Journal of Surgical Oncology 31: 798–802.CrossRef
18.
go back to reference Kiziewicz, A., E. Zekanowska, K. Cieslinski, et al. 2008. Protein C system in patients with idiopathic pulmonary fibrosis—preliminary report. Pneumonologia i Alergologia Polska 76: 225–228.PubMed Kiziewicz, A., E. Zekanowska, K. Cieslinski, et al. 2008. Protein C system in patients with idiopathic pulmonary fibrosis—preliminary report. Pneumonologia i Alergologia Polska 76: 225–228.PubMed
19.
go back to reference Raghu, G., H.R. Collard, J.J. Egan, et al. 2011. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine 183: 788–824.CrossRef Raghu, G., H.R. Collard, J.J. Egan, et al. 2011. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine 183: 788–824.CrossRef
20.
go back to reference Hyzy, R., S. Huang, J. Myers, et al. 2007. Acute exacerbation of idiopathic pulmonary fibrosis. Chest 132: 1652–1658.CrossRef Hyzy, R., S. Huang, J. Myers, et al. 2007. Acute exacerbation of idiopathic pulmonary fibrosis. Chest 132: 1652–1658.CrossRef
21.
go back to reference Pellegrino, R., G. Viegi, V. Brusasco, et al. 2005. Interpretative strategies for lung function tests. European Respiratory Journal 26: 948–968.CrossRef Pellegrino, R., G. Viegi, V. Brusasco, et al. 2005. Interpretative strategies for lung function tests. European Respiratory Journal 26: 948–968.CrossRef
22.
go back to reference Lloyd, C.R., S.L. Walsh, and D.M. Hansell. 2011. High-resolution CT of complications of idiopathic fibrotic lung disease. British Journal of Radiology 84: 581–592.CrossRef Lloyd, C.R., S.L. Walsh, and D.M. Hansell. 2011. High-resolution CT of complications of idiopathic fibrotic lung disease. British Journal of Radiology 84: 581–592.CrossRef
23.
go back to reference Naccache, J.M., and H. Mal. 2011. Management of acute exacerbations of pulmonary fibrosis. Revue des Maladies Respiratoires 28: 517–528.CrossRef Naccache, J.M., and H. Mal. 2011. Management of acute exacerbations of pulmonary fibrosis. Revue des Maladies Respiratoires 28: 517–528.CrossRef
24.
go back to reference Vázquez, J.M., J.M. Dobano, F.J. Barcala, et al. 2011. Acute exacerbation of idiopathic pulmonary fibrosis. Medicina Clinica 136: 403–407.CrossRef Vázquez, J.M., J.M. Dobano, F.J. Barcala, et al. 2011. Acute exacerbation of idiopathic pulmonary fibrosis. Medicina Clinica 136: 403–407.CrossRef
25.
go back to reference Idell, S. 2003. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. American Journal of Respiratory and Critical Care Medicine 31: S213–S220.CrossRef Idell, S. 2003. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. American Journal of Respiratory and Critical Care Medicine 31: S213–S220.CrossRef
26.
go back to reference Pandit, K.V., J. Milosevic, and N. Kaminski. 2011. MicroRNAs in idiopathic pulmonary fibrosis. Translational Research 157: 191–199.CrossRef Pandit, K.V., J. Milosevic, and N. Kaminski. 2011. MicroRNAs in idiopathic pulmonary fibrosis. Translational Research 157: 191–199.CrossRef
27.
go back to reference Kobayashi, H., E.C. Gabazza, O. Taguchi, et al. 1998. Protein C anticoagulant system in patients with interstitial lung diseases. American Journal of Respiratory and Critical Care Medicine 157: 1850–1854.CrossRef Kobayashi, H., E.C. Gabazza, O. Taguchi, et al. 1998. Protein C anticoagulant system in patients with interstitial lung diseases. American Journal of Respiratory and Critical Care Medicine 157: 1850–1854.CrossRef
28.
go back to reference Yasui, H., E.C. Gabazza, O. Taguchi, et al. 2000. Decreased protein C activation is associated with abnormal collagen turnover in the intraalveolar space of patients with interstitial lung disease. Clinical and Applied Thrombosis/Hemostasis 6: 202–205.CrossRef Yasui, H., E.C. Gabazza, O. Taguchi, et al. 2000. Decreased protein C activation is associated with abnormal collagen turnover in the intraalveolar space of patients with interstitial lung disease. Clinical and Applied Thrombosis/Hemostasis 6: 202–205.CrossRef
29.
go back to reference Bogatkevich, G.S., A. Ludwicka-Bradley, P.J. Nietert, et al. 2011. Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease. Arthritis and Rheumatism 63: 1416–1425.CrossRef Bogatkevich, G.S., A. Ludwicka-Bradley, P.J. Nietert, et al. 2011. Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease. Arthritis and Rheumatism 63: 1416–1425.CrossRef
30.
go back to reference Bogatkevich, G.S., A. Ludwicka-Bradley, R.M. Silver, et al. 2009. Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis and Rheumatism 60: 3455–3464.CrossRef Bogatkevich, G.S., A. Ludwicka-Bradley, R.M. Silver, et al. 2009. Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis and Rheumatism 60: 3455–3464.CrossRef
Metadata
Title
Serum Analysis of Coagulation Factors in IPF and NSIP
Authors
E. Bargagli
C. Madioni
N. Bianchi
R. M. Refini
R. Cappelli
P. Rottoli
Publication date
01-02-2014
Publisher
Springer US
Published in
Inflammation / Issue 1/2014
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-013-9706-z

Other articles of this Issue 1/2014

Inflammation 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.